Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3022% above fair value

$465.67−1.39 (-0.30%)

Close on Nov 13, 2026Market cap $251.76BP/E 27.0Yield 2.07%

Amgen EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Amgen's EV/EBITDA was 21.0× on Nov 11, 2026, against 19.4× a year earlier. Over the last 5 years it ranged from 11.8× to 23.1×, with a median of 16.7×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	21.0×	+2.4
2025	Dec 31, 2025	18.6×	−1.8
2024	Dec 31, 2024	20.4×	+5.9
2023	Dec 29, 2023	14.4×	+1.6
2022	Dec 30, 2022	12.9×	+0.7
2021	Dec 31, 2021	12.2×	−1.0
2020	Dec 31, 2020	13.1×	+0.1
2019	Dec 31, 2019	13.0×	+2.1
2018	Dec 31, 2018	10.9×	−2.1
2017	Dec 29, 2017	13.0×	+0.6
2016	Dec 30, 2016	12.3×	−2.8
2015	Dec 31, 2015	15.1×	−3.8
2014	Dec 31, 2014	19.0×	+3.2
2013	Dec 31, 2013	15.7×	+0.0
2012	Dec 31, 2012	15.7×	+4.8
2011	Dec 30, 2011	10.9×	+1.8
2010	Dec 31, 2010	9.1×	−0.0
2009	Dec 31, 2009	9.1×	–